Induction of MOG 35-55 peptide-induced EAE On Day 0, ~12-week-old female mice were immunized subcutaneously with 200 g of MOG 35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) 118 and 400 g of Mycobacterium tuberculosis H37Ra (MTb, Difco, Detroit, MI)
Furthermore, H&E staining showed that compared to the aorta of normal aging mice, the aorta of mice treated with FOXO4-DRI was thinner, and the PWV value was lower in the ultrasound detection results, which means that the mice treated with FOXO4-DRI had better vascular elasticity and better vascular function than normal aging mice (Figures 1D,E)
According to the agreement, Hansoh Pharmaceutical will grant Merck exclusive global rights to develop, manufacture, and commercialize HS-10535
[5] [6] The American College of Cardiology, American Heart Association, and American Diabetes Association now recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, regardless of baseline hemoglobin A1c levels
Pausing peptide use on weekends and cyclically through therapy mimics the rhythm seen in many natural bodily systems
NCT, National Clinical Trial identifier
